

Bamlanivimab Order Form

Patient Name _____ DOB _____

Address _____

Phone # _____ ICD-10 Diagnosis (must check box): U07.1 – COVID-19

*****Bamlanivimab is NOT indicated for hospitalized patients, patients receiving supplemental oxygen, or patients on home oxygen who are requiring increased amounts of oxygen.*****

Patient Risk Factors:

- | | |
|--|---|
| <input type="checkbox"/> Age ≥ 65 | <input type="checkbox"/> Diabetes Mellitus* |
| <input type="checkbox"/> BMI ≥ 35 | <input type="checkbox"/> Age ≥ 55 with COPD* |
| <input type="checkbox"/> Immunosuppressed* | <input type="checkbox"/> Age ≥ 55 with HTN or CAD/CHF |
| <input type="checkbox"/> Chronic Kidney Disease* | |

*Immunosuppressed – patients on immunosuppressive medications or who have immunosuppressive disease (ex. CLL)

*CKD – stage 3 or above

*Diabetes Mellitus – with medications

*COPD – requiring home O2 (but at baseline flow rate)

Patients who have 1 or more of the above risk factors and are within 10 days of symptom onset will be eligible for bamlanivimab treatment.

Symptom Onset Date: _____ Symptoms: _____

Rx:

- IV Bamlanivimab 700mg added to 250 mL of 0.9% sodium chloride for total volume of 270 mL x 1 dose
- Infuse over 1 hour
 - Administer using a 0.2-micron filter
 - Observe patient for at least 1 hour following administration
 - Flush line with normal saline after infusion to ensure complete dose is given

KHN infusion reaction protocol will be utilized if a patient has an infusion-related or hypersensitivity reaction.

Pre-meds (optional):

- Tylenol 650 mg po or Tylenol 1000 mg po
- Benadryl 25 mg po or Benadryl 25 mg IV
- Methylprednisolone 40 mg IV
- Other: _____

Consider premeds for patients with allergic tendencies or who have had allergic reactions to an immunoglobulin product.

Other Comments: _____

Prescriber _____ Date _____

Prescriber Signature _____

Address: _____ Phone _____ Fax: _____